CMPX

Compass Therapeutics, Inc. (CMPX) - Q2 2025 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended June 30, 2025. Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics. The company's pipeline targets angiogenesis and the immune system, with lead candidates including tovecimig (DLL4 x VEGF-A), CTX-471 (CD137 agonist), CTX-8371 (PD-1 x PD-L1 bispecific), and CTX-10726 (PD-1 x VEGF-A bispecific).

Key Financial Metrics

Note: All figures in millions unless otherwise noted. The company reported no product revenue.

Material Changes vs. Prior Period

• Increased Net Loss: Net loss for the three months ended June 30, 2025, increased by $6.8 million (52%) compared to the same period in 2024. For the six months, the loss increased by $12.7 million (53%).
• R&D Expense Growth: Research and development expenses rose by $5.2 million (47%) in Q2 and $8.8 million (42%) YTD. This increase was primarily driven by a $5.7 million (Q2) and $8.2 million (YTD) increase in manufacturing expenses for tovecimig and CTX-10726.
• Revenue Decline: Licensing revenue dropped to zero in 2025, compared to $0.85 million in 2024, which was a milestone payment from Elpiscience.
• Interest Income Decline: Other income (interest) decreased by 40% in Q2 and 36% YTD due to lower cash and marketable securities balances.
• Accrued Expenses: Accrued expenses increased significantly to $10.99 million from $6.29 million at year-end 2024, largely due to $8.2 million in accrued manufacturing expenses, including $3.6 million in minimum contractual obligations for CTX-10726.

Guidance, Outlook, and Risks

• Liquidity Outlook: Management expects current cash resources ($101 million) to fund operating expenses and capital expenditures into 2027.
• Clinical Updates:
  • Tovecimig: Phase 2/3 study in biliary tract cancer met its primary endpoint (17.1% ORR). Secondary endpoint analyses (OS/PFS) are now expected in Q1 2026 due to fewer observed deaths than modeled.
  • CTX-8371: Phase 1 data supports cohort expansion in NSCLC and triple-negative breast cancer, expected to initiate in Q4 2025.
  • CTX-10726: Preclinical studies showed superiority to ivonescimab. IND submission is planned for Q4 2025.
• Risks:
  • Capital Needs: The company will require substantial additional funding to continue operations and commercialize products. Failure to raise capital could force delays or reductions in development.
  • Regulatory & Pricing: New Executive Orders (14273 and 14297) regarding drug pricing and "Most-Favored-Nation" pricing targets pose risks to future reimbursement and profitability.
  • Development Uncertainty: No assurance exists that product candidates will obtain regulatory approval or achieve commercial viability.

Key Facts for Investor Verification

• Cash Runway: Verify the sustainability of the "into 2027" liquidity projection given the accelerating burn rate (YTD cash used in operations was $25.0 million).
• Manufacturing Accruals: Confirm the nature and timing of the $8.2 million increase in accrued manufacturing expenses, specifically the $3.6 million minimum obligation for CTX-10726.
• Tovecimig Trial Status: Monitor the Q1 2026 timeline for the secondary endpoint analysis of the Phase 2/3 biliary tract cancer study, which is critical for regulatory pathways.
• Regulatory Environment: Assess the potential impact of the new Trump Administration Executive Orders on drug pricing strategies for future commercialization.
• Stock-Based Compensation: Note the remaining unrecognized stock-based compensation cost of $24.8 million, which will impact future operating expenses.